5 recruiting, 2 active not recruiting, 2 completed. 7 Phase 2, 3 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Recruiting 4, Completed 2, Active not recruiting 1 |
| Phase 3 | 3 | Active not recruiting 2, Recruiting 1 |
| Not applicable | 1 | Recruiting 1 |
Follow Biphenotypic Acute Leukemia: new trials by email Literature Review of Biphenotypic Acute Leukemia trials Research Report on Biphenotypic Acute Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis Conditioning regimen: Treosulfan 42 g/m2/course or total body irradiation 12 Gray/course, Etoposide 60 mg/kg , Fludarabine 150 - Biphenotypic Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 50 | 2024-07-10 | 2025-01-01 |
| BeFluBu vs FluBuRux Conditioning in Haploidentical HCT Bendamustine Hydrochloride, Ruxolitinib - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | St. Petersburg State Pavlov Medical University | 220 | 2024-06-21 | 2024-06-27 |
| Vitamin A and D Supplementation in Allogeneic HCT Vitamin A, Vitamin D3 - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | St. Petersburg State Pavlov Medical University | 220 | 2024-05-15 | 2024-07-31 |
| Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis Baricitinib - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 / Phase 3 | Active not recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 150 | 2023-12-01 | 2024-08-23 |
| Allo HSCT Using RIC and PTCy for Hematological Diseases Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 56 | 2023-05-01 | 2026-07-06 |
| MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi) - Leukemia, Acute Myeloid Leukemia in Remission | Not applicable | Recruiting | Medical College of Wisconsin | 40 | 2023-05-01 | 2026-05-13 |
| Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor - Acute Lymphoblastic Leukemia, Myeloblastic Leukemia | Phase 3 | Active not recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 56 | 2022-08-23 | 2023-09-28 |
| Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe) Fludarabine, Bendamustine Hydrochloride, Busulfan - Leukemia, Acute Lymphoblastic, Myeloid Leukemia, Acute | Phase 2 | Completed | St. Petersburg State Pavlov Medical University | 50 | 2021-01-21 | 2024-05-07 |
| Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies Fludarabine, Melphalan, Total Body Irradiation - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 34 | 2019-12-06 | 2025-12-11 |
Leukemia, Biphenotypic, Acute (9) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (9) · Myelodysplastic Syndromes (8) · Leukemia, Myeloid, Acute (6) · Myeloproliferative Disorders (4) · Burkitt Lymphoma (3) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myelomonocytic, Acute (2) · Leukemia, Prolymphocytic (2) · Lymphoma (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2) · Lymphoma, Non-Hodgkin (2) · Lymphoma, T-Cell (2)
Bone Marrow Diseases (9) · Hematologic Diseases (9) · Hemic and Lymphatic Diseases (9) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Leukemia, Lymphoid (9) · Lymphatic Diseases (9) · Lymphoproliferative Disorders (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Leukemia (8) · Leukemia, Myeloid (8) · Lymphoma (5) · Chronic Disease (4) · Disease Attributes (4)
Cyclophosphamide (3) · fludarabine (3) · Abatacept (2) · Bendamustine Hydrochloride (2) · Mycophenolic Acid (2) · Whole-Body Irradiation (2) · vedolizumab (2) · Allopurinol (1) · Busulfan (1) · Calcineurin Inhibitors (1) · Capsules (1) · Cholecalciferol (1) · Etoposide (1) · Melphalan (1) · Peripheral Blood Stem Cell Transplantation (1)
Federal Research Institute of Pediatric Hematology, Oncology and Immunology (3) · St. Petersburg State Pavlov Medical University (3) · H. Lee Moffitt Cancer Center and Research Institute (1) · Masonic Cancer Center, University of Minnesota (1) · Medical College of Wisconsin (1)
Russia (6) · United States (3)
Mark Juckett (1) · Nelli Bejanyan, MD (1)